I’ve been a health journalist for twelve years. I’ve covered diabetes, cardiovascular disease, women’s health, and now the GLP-1 revolution. And I don’t think I’ve ever been this angry about an information gap.
Three out of four people taking GLP-1 medications are women. 76%. Not a slight majority — an overwhelming one. In any other area of medicine, a patient population that skewed this heavily female would have triggered dedicated clinical guidelines, specialized content, and prescribing protocols that acknowledge who’s actually sitting in the exam room.
Instead, we got generic medication guides written for nobody in particular. Male-default clinical trial designs. And a content landscape that treats women’s specific concerns as footnotes — if it mentions them at all.
My sister started Ozempic last spring. Smart woman — reads everything, asks great questions. She searched “how to take Ozempic” and found a hundred articles. Not one mentioned menstrual cycles. Not one mentioned fertility. Not one mentioned that women metabolize this drug differently than men. She only learned about the luteal phase nausea spike from a stranger in a Facebook group at midnight.
That’s not an oversight. It’s a systemic failure. And I’m done being polite about it.
The Clinical Trial Problem
The landmark semaglutide trials — STEP 1 through STEP 5 — did include women. Roughly half to two-thirds of participants were female (Wilding et al., 2021). But “including women” and “studying women’s specific responses” are very different things, and the gap between those two sentences is where women’s health goes to die.
The trials measured weight loss, HbA1c, cardiovascular outcomes, and standard adverse events. Here’s what they did not systematically track: menstrual cycle changes. Fertility outcomes. Interactions with hormonal contraception. Differences in side effect severity across the menstrual cycle. Impact on perimenopause symptoms. Sex-specific body composition changes. Psychological effects specific to women’s relationship with food and body image.
Seven blind spots. For a drug used by 76% women.
When the FDA approved semaglutide for obesity, it came with zero sex-specific dosing guidelines. Zero guidance on contraception management. Zero protocols for menopausal women. A drug overwhelmingly used by women arrived with nothing designed for women. I’ve been covering healthcare long enough that this shouldn’t surprise me anymore. It still does.
What Women Experience That Men Don’t
The luteal phase from hell. Nausea peaks during the two weeks before your period when progesterone is high. Progesterone slows gastric motility. So does semaglutide. Stack them together and you get a two-week window of amplified GI misery that has nothing to do with your dose and everything to do with your hormones.
My neighbor Jess figured this out by tracking her symptoms in a period app for three months. Her doctor hadn’t mentioned it. Her pharmacist hadn’t mentioned it. A woman named @GLP1goddess on Reddit explained it in a post with 4,000 upvotes. That’s where we are.
The fertility surprise nobody warns about. Women with PCOS, obesity-related anovulation, or “unexplained” infertility are getting pregnant on GLP-1 drugs — often without trying. A meta-analysis showed a 72% higher natural pregnancy rate (Jensterle et al., 2023). But semaglutide isn’t approved during pregnancy, and animal studies raise teratogenic concerns. A drug that boosts fertility comes with zero reproductive counseling at the pharmacy counter. I wrote an entire piece about this because it made me so angry.
The muscle loss that compounds everything. Women start with less muscle. Lose it more easily. Regain it more slowly. During perimenopause, you’re already losing muscle from declining estrogen. When semaglutide’s lean mass loss stacks on top of menopausal sarcopenia, the result isn’t just a number on a DEXA scan — it affects bone density, metabolic rate, and whether you can carry your groceries up the stairs at 65.
My mom is 62 and asked me about Ozempic last Christmas. The lean mass conversation was the first thing I brought up. Not the nausea. Not the cost. The muscle, because nobody else was going to tell her.
The contraception gap that scares me most. GLP-1 drugs cause nausea, vomiting, and diarrhea. Oral contraceptives require consistent GI absorption. If you’re throwing up or having diarrhea several times a week, your birth control pills may not be working. For a drug that simultaneously increases fertility and potentially compromises contraception, the silence from prescribers is genuinely dangerous.
Why This Content Gap Exists
I’ve spent enough time in health media to understand the machinery behind the silence.
Medical content defaults to male. Heart attack symptoms, pain medication dosing, even crash test dummies — they were designed around male bodies until embarrassingly recently. GLP-1 content inherited the same bias on autopilot.
SEO incentives reward generic content. “What is Ozempic” gets more searches than “Ozempic and menstrual cycle.” Content farms chase volume over specificity every time. The algorithm doesn’t care about your luteal phase.
Liability departments suppress specificity. Writing about contraceptive interactions is a legal risk most publishers won’t take. Easier to write another “talk to your doctor” paragraph and call it a day.
And the foundational problem: the women-specific data barely exists. The research gap creates a content gap creates a clinical care gap. It’s gaps all the way down.
What Women Built Instead
In the absence of clinical guidance, women built their own knowledge infrastructure. Reddit’s GLP-1 communities. Facebook groups with hundreds of thousands of members. Group chats. Y’all did what women have always done when the system fails — you figured it out together and shared notes.
These communities have collectively generated more practical, women-specific GLP-1 knowledge than the entire clinical trial program. As a journalist, I find that both remarkable and infuriating in equal measure.
The Access Layer Makes Everything Worse
Here’s the dimension that keeps me awake: the women most in need of women-specific guidance are increasingly outside the traditional medical system entirely. The compounding ban displaced over a million patients. Research-grade semaglutide — the same molecule, available from online vendors at $40-80 per vial instead of $935/month branded — has become the primary access point for a huge number of women.
Those women have no prescriber. No pharmacist. No one to explain the menstrual cycle interaction, the fertility effect, the lean mass concern. They’re relying entirely on community knowledge and content like what you’re reading right now.
Let me be blunt: that’s not ideal. But it’s reality. And if the medical system won’t provide women-specific GLP-1 guidance through official channels, then it needs to exist somewhere accessible. The information gap shouldn’t be wider just because you chose the affordable access route.
What Needs to Change
Sex-stratified clinical trial reporting. The raw data exists — publish the analyses by sex. Every time. No exceptions.
Reproductive counseling at point of prescription. Every woman of reproductive age getting a GLP-1 script needs a fertility and contraception conversation. Period.
Body composition endpoints alongside weight. Stop measuring success only in pounds lost when the thing that matters is what kind of weight you’re losing.
Menstrual cycle interaction studies. One moderately sized study could characterize the cyclical side effect pattern properly. One. The fact that it hasn’t been done tells you everything about priorities.
And content — content that speaks to women as the primary users, not edge cases. When three-quarters of your patients are women, women aren’t a special population. They’re the population.
Until that changes, women on GLP-1 drugs will keep doing what they’ve always done: figuring it out themselves, sharing what works, and compensating for a system that wasn’t built for them.
I started this site because I watched too many smart, capable women — women like my sister, like Jess, like my mom — make decisions about their GLP-1 treatment based on information that wasn’t written for them. Whether you’re using a branded Ozempic pen with full insurance coverage or reconstituting research-grade semaglutide at your kitchen counter, you deserve the same quality of information.
That’s the hill I’m on. I’m not coming down.
References:
Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).” N Engl J Med. 2021;384:989-1002.
Jensterle M, et al. “GLP-1 Receptor Agonists in PCOS: A Systematic Review and Meta-Analysis.” Front Endocrinol. 2023.
Gasoyan H, et al. “Insurance Coverage of Anti-Obesity Medications.” Obesity. 2024.
Zucker I, Prendergast BJ. “Sex differences in pharmacokinetics predict adverse drug reactions in women.” Biol Sex Differ. 2020;11:32.